ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2010
Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Rifampin-accompanied antibiotic regimens in the treatment of prosthetic joint infections: a frequentist and Bayesian meta-analysis of current evidence.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Pooled it
- Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial.Journal of orthopaedic surgery and research · 2020Trial
- Pharmacological Intervention for Refractory Biofilm Infection After Hemipelvic Replacement Surgery: Multidisciplinary Management of a Case of Giant Cell Tumor of Bone.The American journal of case reports · 2025Article
- [Debridement, antimicrobial therapy, and implant retention for acute periprosthetic infections].Orthopadie (Heidelberg, Germany) · 2025Review
- Organism profiles and empirical treatments for periprosthetic joint infections.Journal of orthopaedic surgery and research · 2025Article
- Oral tetracyclines for bone and joint infections: what do we know?Journal of bone and joint infection · 2025Review
- The impact of rifampin on the efficacy of implant retention and prosthesis removal in staphylococcal periprosthetic joint infection.Frontiers in cellular and infection microbiology · 2025Article
- Debridement, antimicrobial therapy, and implant retention (DAIR) as curative strategy for acute periprosthetic hip and knee infections: a position paper of the European Bone & Joint Infection Society (EBJIS).Journal of bone and joint infection · 2025Article
- The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence.Antibiotics (Basel, Switzerland) · 2024Review
- Diagnosis and Treatment of Acute Periprosthetic Infections with the BioFireBiomedicines · 2024Review
- Early Staphylococcal Periprosthetic Joint Infection (PJI) Treated with Debridement, Antibiotics, and Implant Retention (DAIR): Inferior Outcomes in Patients with Staphylococci Resistant to Rifampicin.Antibiotics (Basel, Switzerland) · 2023Article
- Adverse Events Associated with Prolonged Antibiotic Therapy for Periprosthetic Joint Infections-A Prospective Study with a Special Focus on Rifampin.Antibiotics (Basel, Switzerland) · 2023Article
- Principles of mechanical and chemical debridement with implant retention.Arthroplasty (London, England) · 2023Review
- A review of current practices in periprosthetic joint infection debridement and revision arthroplasty.Arthroplasty (London, England) · 2022Review
- Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections.Open forum infectious diseases · 2022Article
- Microbiological and Molecular Features Associated with Persistent and RelapsingAntibiotics (Basel, Switzerland) · 2022Article
- Tuning the Drug Release from Antibacterial Polycaprolactone/Rifampicin-Based Core-Shell Electrospun Membranes: A Proof of Concept.ACS applied materials & interfaces · 2022Article
- Superinfection with Difficult-to-Treat Pathogens Significantly Reduces the Outcome of Periprosthetic Joint Infections.Antibiotics (Basel, Switzerland) · 2021Article
- Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.Open forum infectious diseases · 2021Review
- Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France.BMC infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R). We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy. The effect of the use of a rifampin-based regimen was evaluated. Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders. Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF. After controlling for the propensity to treat with rifampin and American Society of Anesthesia scores, patients in the prospective cohort had a lower risk of TF compared to patients in the historical cohort not treated with rifampin (HR 0.11; 95%CI 0.01-0.84). None (0/14) of the patients in the prospective study developed hepatotoxicity. The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.